Please assess the completion status of the following clinical trial:

Trial Title: 0.5M Na Lactate Solution in Acute Heart Failure (AHF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: more than 18 years~* Heart failure criteria:~Left heart failure: as evidenced by 2 out of 3:~* Left ventricular ejection fraction (LVEF) ≤ 40% and cardiac index ≤ 2.5 L/min/m2~* Acute pulmonary oedema of cardiac origin or mechanical ventilation (including CPAP/BIPAP) for respiratory failure of predominantly cardiac origin~* Need for inotropes/vasopressors for cardiac pump failure OR~Right heart failure: as evidenced by 1 out of 2:~* Bilateral leg oedema above ankles~* RV failure (low tricuspid annular plane systolic excursion (TAPSE), dilated floppy RV)~* Poor peripheral perfusion as evidenced by 2 out of 3:~Cold mottled skin Low urine output Acutely clouded sensorium/poor mentation~* Consent obtained from patient or patient's next of kin.~Exclusion Criteria:~* Hypernatremia: \[Na\] \>145 mmol/L~* Diagnosed hypertrophic obstructive cardiomyopathy~* Uncorrected severe valvular heart disease~* Documented third degree heart block, sustained ventricular tachycardia~* Documented cardiac tamponade~* Septic shock~* Acute respiratory distress syndrome (ARDS)~* Moribund patients likely to die before 24h~* Patients with major diseases of limited prognosis such as end stage cancer,end-stage liver failure, end stage dialysis dependent renal failure~* Patients with absolute indication for acute hemodialysis/hemofiltration (pH, K, urea \> 35 mmol/L, severe fluid overload in the presence of oliguria \< 200 mL/6h.~* Known pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5M Sodium lactate (Type: EXPERIMENTAL): A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
- Hartmann's solution (Type: ACTIVE_COMPARATOR): Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).